The Body as a Business: Why Lookmaxxing Is a Capital Allocation Story
Lookmaxxing was all fringe, obsessive, and a little unhinged in the mid-2010s. Like the big egos and conspiracies that would come before it, it started on the dark ends of incel forums. Then TikTok happened. Then Merriam-Webster added it to the official lexicon. Suddenly it was everywhere. Normalized. Packaged. Sold back to the same people it used to mock.
What happened: the body stopped being something you inherit and became something you build. Biology went from destiny to a project management problem.
You can tell where the dollars are going by looking at the injection sites.
One in eight Americans shoot GLP-1s weekly. Ozempic alone drives $20 billion a year. Medspas are booming. There's an underground peptide market bubbling up on TikTok. Fractionalized, science-backed subsectors within skincare are emerging. It might look like three separate industries, but really it's one big consumer appetite wearing different masks. The self-optimization economy — and globally it's currently moving north of $2 trillion.
The people who will get cooked are investors who still see three separate verticals. The ones who find the winners are those who see one market with three capture mechanisms.
We're on a mission to identify listed equities benefiting from this wave of spending — using margin and execution as our only filters.
Market Size: What Is the Actual Size of the Lookmaxxing Economy?
The number might blow your brains out.
But that's just the opening act.
| Market | Size | Growth Rate |
|---|---|---|
| Beauty Retail Industry (Global) | $441B [2024] | CAGR of 5% through 2030 |
| Aesthetic Injectables Market | $140B [2024] | CAGR of 9–12% through 2030 |
| Wellness Market (US) | $500B/yr | 4% to 5% growth |
| Global Wellness | $2T | Baseline context |
Structural shift: 22% of US consumers used beauty and spa services in 2023. In 2025, that number went to 33%. Two years. That's not a trend flickering on and off. That's a before-and-after.
- Year-over-year growth of 6% for skin resurfacing
- Year-over-year growth of 4% for neuromodulator injections (Botox etc.)
- $140B global aesthetic injectables market — 9–12% CAGR through 2030
What makes the recession-resistance point stick: in 2008 while people were losing their homes, vitamins grew by 6%. And 84% of US consumers rank wellness as a top priority. Not "say they do." Actually rank it. This is not vanity. It's infrastructure.
Here's how the flywheel loops: social media generates attention → attention sparks product discovery → discovery draws people closer to pharmaceuticals → pharmaceuticals drive peptide normalization → peptides pull in social validation. Each rotation brings in more money. Each loop pulls in more people. It gains momentum.
The GLP-1 Catalyst: How Ozempic Unlocked the Entire Stack
Around 2020, Ozempic took on a new role. It was no longer exclusively a diabetes drug — it became a permission slip.
Before GLP-1s came into the picture, there was stigma around optimization. Trying to design your own body? Vain. Weak. Cheating. Then Ozempic hit the mainstream and that entire moral framework dissipated. Pharmacological self-improvement wasn't cheating anymore. It was medicine. It was science. The rebranding was flawless. Genuinely flawless.
| Metric | Figure |
|---|---|
| Usage growth of GLP-1 for youth aged 12–25 (2020–2023) | 594% |
| % of 14- to 24-year-olds who've heard of Ozempic/Wegovy | 73.6% |
| % of obese teens prescribed | 2.9% |
Look at kids taking GLP-1s who aren't obese. They don't have diabetes. They're lean, aesthetic-focused, and they're using a weight-loss drug to get leaner. The medical apparatus just handed the keys over.
With GLP-1 going mainstream, the psyche barrier against peptides was broken. GLP-1's mass adoption did not only normalize injectable aesthetics drugs — it collapsed the psychological barrier to the entire peptide stack.
Ozempic is creating its downstream market. Those who experience "Ozempic face" — losing fat quickly, looking hollow and aged — are now creating demand for MedSpa fillers. Drug causes the problem. Clinic fixes it. Then retatrutide, a triple agonist drug hitting clinical trials soon, will escalate this conversation again and have people asking for the stack. Meanwhile, 46% of US consumers spent more on cosmetics in 2024 than 2023. Gen Z hit 53%.
The MedSpa Industry: Structure, Scale, and Who Captures the Margin
Medical spas — non-invasive cosmetic procedures under medical oversight — is where real cash is flowing right now, in boutique clinics and strip malls across the US. Not a theoretical idea.
The core revenue stack: injectables (Botox, Dysport, fillers), laser treatments and microneedling, body sculpting. The smartest operators are layering in regenerative treatments — PRP, exosomes — and integrated wellness: IV therapy, hormone optimization, weight loss programs. Each service extension is another hook. Another reason your credit card is already out.
Structure = opportunity. We see a lot of single-location operators with average annual revenue of $2M. Fragmented. Unscaled. Leaving money on the table. 44% of Gen Z discover procedures on social media. Demand that literally perpetuates itself.
| Demographic | Today | Trajectory |
|---|---|---|
| Female consumers | ~90% | Stable baseline |
| Core age band | 35–54 | Shifting younger |
| Male injectable demand | Growing | Doubles by 2028 |
| Gen Z adopters | Growing fast | Self-reinforcing (social discovery) |
The younger crowd is all about natural-looking preventative stuff — Botox at 25, not 45. The psychology has already moved. Nobody's waiting until 45 anymore. That fragmentation is a screaming consolidation signal. As mom-and-pop clinics leave money on the table, PE rollups and scaled operators are capturing that margin. Single location = inefficiency. Chain = leverage. The question is who's going to own the infrastructure that comes next.
Peptides: The Underground Goes Public
What comes after MedSpa saturation? The real edge is after the procedure — in the recovery, in the cellular-level optimization that traditional medicine hasn't packaged yet. That's where peptides live.
Peptides are small chains of amino acids — 2–50 in number — that mimic your body's own hormones and growth factors with high specificity and minimal side effects.
- BPC-157 — tissue repair, gut barrier function. An epic recovery peptide. Run it after an injury or procedure and your body just heals faster.
- GHK-Cu — collagen synthesis, skin remodeling. Now making the leap to mainstream skincare formulators. This isn't fringe anymore; it's in your skin cream.
- CJC-1295 — growth hormone release. Stack it with Ipamorelin for muscle and fat composition. This is where the underground gets clinical.
The FDA regulatory grey zone is real. And the community often reads silence as consent. Thousands of people have already tested, refined, and validated underground protocols. Once you've injected a hormone to lose fat, the leap to peptides isn't scary anymore. It's obvious.
GLP-1's mass adoption didn't just normalize injectable drugs in aesthetics. It collapsed the psychological barrier to peptides entirely.
That's not speculation. That's $5B saying: we got here first.
Top 5 US-Listed Stocks Best Positioned for the Lookmaxxing Wave
These five names own the distribution channels, manufacturing scale, brand moat, and direct-to-consumer relationships that will funnel trillions into self-optimization. They're not moonshot biotech bets. They're positioned at the exact center where the money flows.
| Stock | Core Business | 2024 Rev Signal | Margin Profile | Why It Matters |
|---|---|---|---|---|
| NVO | Ozempic/Wegovy | $20B+ Ozempic baseline | Best-in-class operating margins | Gateway drug for injector normalization |
| LLY | Mounjaro/tirzepatide | $34B+ run rate | Strong biologic gross margins | Direct NVO competitor with scale |
| ABBV | Botox + Juvederm | $3.9B combined injectables | 83.9% adjusted gross margin | Consumer-facing aesthetics moat |
| INMD | RF/laser body contouring | ~$394M | 80% GAAP gross margin | MedSpa infrastructure pure play |
| HIMS | Telehealth + compounding | Strong growth trajectory | Compounding margin expansion | Direct-to-consumer distribution moat |
The Gateway Stock
Novo makes Wegovy and Ozempic. Its $20B revenue stream is more than just revenue — it's the permission structure for everything that comes next. As people normalize semaglutide for weight loss, the stigmatization of peptides goes away entirely. Boom. The underground goes mainstream.
It got to $20B faster than any drug in history. Novo has some of the highest operating margins in pharma. Treat this as a core allocation, not a hedge.
The Competitor Play
Tirzepatide (Mounjaro) is not Ozempic. It's a GLP-1/GIP dual agonist. Early data showed faster fat loss with better muscle retention. Running a $34B+ revenue run rate and expanding manufacturing capacity right now. Biologics have legitimately fat margin.
The question: does Lilly eat Novo's lunch, or do they split the market? Right now nobody knows. This is the blue-chip hedge on NVO concentration risk.
The Recurring Revenue Moat
With the Allergan acquisition, they got Botox Cosmetic ($2.72B in 2024) and Juvederm Collection ($1.18B). That's $3.9B in injectables at 83.9% adjusted gross margin. Yes, you read that right.
These are not one-time procedures. Botox wears off every 3–4 months. Fillers migrate. Consumers keep coming back. It's the subscription model baked into biology. And AbbVie proved they could integrate Allergan without ruining channel relationships. That's execution.
The MedSpa Infrastructure Play
Develops minimally invasive laser and RF body contouring devices. InMode is essentially only exposed to the MedSpa infrastructure channel. The vision: elegant machines replacing surgical procedures in MedSpa clinics. Gross margin at 80% GAAP, net margin at 46%. Rare profitability for a medtech at this stage.
Revenue normalized post-pandemic, but InMode managed it with solid margin leadership. Higher beta hardware play in a world of software PoC winners. Volatility is real. Plays into speculative appetites.
The Last-Mile Distribution Play
Telehealth, compounded GLP-1 distribution, and direct-to-consumer aesthetics — full consumer self-optimization relationships, end-to-end. Revenue growth trajectory is there. The risk: compounding regulatory risk is real. The FDA could blow it up tomorrow. Size it accordingly.
But if they deliver — they own the last mile. The distribution moat that actually matters in a world where the product is increasingly commoditized.
For investors who can stomach volatility, higher-beta names like INMD and HIMS can fit. Blue-chip aesthetics plays like ABBV belong in your core. NVO and LLY split the difference with blue-chip exposure to a secular boom. Risk tolerance isn't just a phrase. It's how you size.
The real question isn't which one will win. It's whether you position for the possibility that they all do.
Special Mentions: IPOs, Private, and PE-Style Plays
While the Top 5 are the visible play — the asymmetry is in what PE is quietly hoovering up, and where Altman and Bezos are parking serious capital in places that haven't IPO'd yet.
MedSpa Rollup Platforms (Approaching IPO)
PE has made profit-chasing fragmentation a sport. Collapse 20 single-location clinics earning $2M each into one platform with central admin and a single brand. Pitch a 5x multiple on $40M in revenues. That's the whole trick. The IPO pop is already baked in.
Branded Peptide Platforms (Private)
Someone will win by doing what pharma can't: build brand trust around grey-zone products. Quality control. A subscription that doesn't feel like buying research chemicals. Whoever owns that relationship owns a greenfield. Margins will be obscene.
Revance Therapeutics (RVNC)
Aesthetics pure-play with speculative bent. Lead product DaxibotulinumtoxinA lasts longer than Botox. Road to profitability is murky — kept it out of the Top 5. But if you're comfortable with the risk: speculative neuromodulator upside without a blue-chip price tag.
Longevity Biotech (Venture Stage)
Pre-public: Altos Labs (Bezos), Retro Biosciences (Altman's $180M), NewLimit (Thiel). The anti-aging market will grow at 21.5% CAGR to $421 billion by 2030. Early exposure means going private and hanging in for the long haul if you can stomach the illiquidity.
Analyst Verdict: One Market, One Secular Tailwind
MedSpa, aesthetics injectables, and peptide biotech aren't separate markets. They're one demand curve. One psychological shift through everything. GLP-1 didn't create this wave — it reset the floor. It normalized the notion of injecting your way to a better self. Everything downstream (fillers, lasers, peptides, longevity biotech) is riding that tide. The psychological barrier crumbled. The floodgates are open.
Consider the unit economics. Botox prints at ~84% adjusted gross margins. InMode at 80% GAAP. Recurring revenue. High-leverage unit economics. More structurally obscene than narratively compelling. This is the kind of margin profile that makes capital allocators lose sleep.
The winners aren't selling Botox. They're selling the ecosystem.
Capital hasn't fully flowed into all of this yet. Parts of it are still frontier. But the opportunity is here: the team that owns the platform layer — recurring model, structure, trust, brand, infrastructure — owns the entire stack. Not the product. The platform.
That's where the cheddar lives.
When Dharma Decays — Capital Compounds. — Kalyug Capital